Association between cannabis use and clinical outcomes in patients with solid malignancies receiving immune checkpoint inhibitors

Abstract Background: Cannabis (CAN) use has risen significantly over the last few decades. CAN has potent immunosuppressive properties, which could antagonize the effect of immunotherapy (IO). The impact of CAN use on clinical cancer outcomes remains unclear. Objectives: In this study, we evaluated the clinical effect of CAN use on clinical outcomes among patients with solid malignancies receiving IO. Design: This is a retrospective cohort study of all patients with solid malignancies receiving IO between August 2014 and August 2018.